Enjoy complimentary customisation on priority with our Enterprise License!
Eosinophilic esophagitis is a chronic immune-mediated disorder of the esophagus that affects individuals of all age groups including both adults and children. This disorder is also known as asthma of the esophagus. Patients suffering from this condition are diagnosed with a large number of white blood cells in the tissues of the esophagus. These white blood cells are known as eosinophils. Factors such as the damage to the esophagus, multiplication of eosinophils, and reaction of the esophagus can result in eosinophilic esophagitis disorder. Technavio’s market research analysts have predicted that with the introduction of dietary therapy, proton pump inhibitor (PPI), and topical steroid as some of the most promising investigational approaches to treat eosinophilic esophagitis, the eosinophilic esophagitis market size, and share will increase in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that almost the same amount of drug molecules comes under the phase II drug development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the pre-registration and phase III stage.
This pipeline analysis report mentions the eosinophilic esophagitis market opportunity and provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of eosinophilic esophagitis. In addition to providing information on the various stages of molecules developed by companies for different drug development landscape, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The oral route of administration (ROA) involves the administration of drugs through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
According to this pipeline analysis report, some of the molecules that are currently in the drug development pipeline for eosinophilic esophagitis are being developed as monoclonal antibodies. Monoclonal antibodies bind to only one substance in the body as they are made by identical immune cells that are all clones of a unique parent cell.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.